Produktneuigkeiten Hier finden Sie die neuesten Produktinformationen
-
Obtained CE-IVD marking for Anyplex™ II Thrombosis SNP Panel Assay
Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the blood flow of the cardiovascular system. Several thrombosis associated single nucleotide polymorphisms (SNPs) have been identified and reported to significantly increase the risk of venous thrombosis. One SNP (G20210A) in the Factor II gene has been found to be associated with increased prothrombin levels and an increase in the risk for venous thrombosis in heterozygotes. Three SNPs (R506Q, H1299R and Y1702C) in the factorⅤ genes are one of the most important genetic risk factors for inherited thrombophilia. Two SNPs (C677T and A1298C) in the MTHFR gene cause reduction of MTHFR enzyme activity and heterozygosity for both C677T and A1298C is considered to be a risk factor for venous thrombosis. Anyplex™ II Thrombosis SNP Panel Assay is designed to detect and discriminate six SNPs (1 in Factor II, 3 in Factor V and 2 in MTHFR) in a single tube using the mTOCE™ technology.Anyplex™ II Thrombosis SNP Panel Assay Simultaneous detection of Six SNPs in Factor II, Factor V, and MTHFR genesAnyplex™ II Thrombosis SNP Panel Assay is designed to detect and discriminate six SNPs (1 in Factor II, 3 in Factor V and 2 in MTHFR)
Aug 01, 2014｜ Anyplex™Ⅱ Thrombosis SNP Panel Assay
-
Obtained CE-IVD marking for Anyplex™ BRAF V600E Real-time Detection
Anyplex™ BRAF V600E Real-time DetectionDetection of BRAF V600E Mutation Seegene's Anyplex™ BRAF V600E Real-time Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.NOT AVAILABLE IN US
Sep 24, 2010｜ Anyplex™ BRAF V600E Real-time Detection
-
Launched Anyplex™ BRAF V600E Real-time Detection
Anyplex™ BRAF V600E Real-time DetectionAnyplex™ BRAF V600E Real-time Detection is designed to detect BRAF mutation (V600E) characteristic for papillary thyroid carcinoma from samples of thyroid tissue, FNAB, H&E slides and paraffin-embedded tissues. NOT AVAILABLE IN US The BRAF gene involves in mediating cellular response to growth, differentiation and death signals in RAS → RAF → MEK → MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1), 2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26 ? 69% (likely 45-50%) of all cases1), 3). Anyplex™ BRAF V600E Real-time Detection tests BRAF mutation, the most common genetic mutation in PTC, with single PCR reaction by utilizing DPO™ technology. 1) M Xing. BRAF mutation in thyroid cancer, Endocrine-Related Cancer, 2005, 12, 245-262. 2) Wojciechowska K andLewinski A: BRAF Mutations in Papillary Thyroid Carcinoma, Endocrine Regulations, 2006, 40, 129-138. 3) Ki-wook Chung et al. Clinical Endocrinology, 2006, 65, 660-666.
Aug 13, 2010｜ Anyplex™ BRAF V600E Real-time Detection
-
Upgrade!! DNA Walking™ kit II.
DNA Walking™ kit II. A kit to identify unknown sequences adjacent to upstream or downstream known sequences Seegene's website has been upgraded with newly released "DNA Walking™ kit II". The ordering information, examples, contents, and features of "DNA Walking™ kit II" have been added into Seegene's website. NOT AVAILABLE IN US
-
Grand Launching!-GeneXP™ Kit
GeneXP™ Kit a one-time analysis tool for investigating gene expression pattern ?GeneXP™ kits is Seegene’s original DSO™ -based multiplex RT-PCR system. -Only a single reaction in necessary to amplify multiple genes of interest. -One reaction is sufficient to amplify multiple genes simultaneously in a single reaction. Key Feature *Systematic Analysis of Gene Family Expression *High Specificity & Sensitivity using by DSO™-based multiplex RT-PCR *No more confirmation step required *Hot start Taq DNA Polymerase used Apllications *Comparison of normal vs. diseased tissue EX. normal vs. tumor, non-infected vs. infected, wild type vs. knock-out *Time courses EX. developmental stage, environmental change *Test of influence of Chemical compounds EX. Drug, chemical, hormone, post-clinical treatments *Microarray data validation, etc. For more information, visit our website or call us anytime. http://www.seegene.com/en/product/xpkit_1_introduce.php TEL:(1)301 866 733 4949 FAX:(1)301 866 733 4955
-
Launched DNA Walking Service
DNA Walking Service Launched DNA Walking Service A kit to identify unknown sequences adjacent to upstream or downstream known sequencesDNA Walking SpeedUpTM kit provides information about unknown sequences adjacent to upstream or downstream known sequences. Previous methods commonly used for this purpose include inverse PCR (IPCR), ligation-mediated PCR (LM-PCR) and randomly primed PCR (RP-PCR). Although these methods have been used efficiently and have proven to be effective, they are still hampered by laborious steps such as restriction enzyme digestion, adaptor ligation, and purification procedures. Moreover, arbitrary pimers in RP-PCR often result in non-specific products due to non-specific annealing. These drawbacks of existing genomic walking methods can be overcome by employing Seegene's proprietary ACPTM (Annealing Control Primer) Seegene developed DNA walking technology by incorporating ACPTM (Annealing Control Primer) and DPOTM (Dual Priming Oligonucleotide) technologies, which maximize the specificities of short primers and target specific primers, respectively, and furnishes optimized data about unknown sequences. Note! DNA WalkingTM kit II, which provides widen application and higher success ratio than DNA WalkingTM kit I, has been recently released. NOT AVAILABLE IN US
